Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

A single, high linear energy transfer alpha particle can kill a target cell. We have developed
methods to target molecular-sized generators of alpha-emitting isotope cascades to the …

Unlike β particle–emitting isotopes, α emitters can selectively kill individual cancer cells with
a single atomic decay. HuM195, a humanized anti-CD33 monoclonal antibody, specifically …

Single-walled carbon nanotubes (CNT) are mechanically robust graphene cylinders with a
high aspect ratio that are comprised of sp 2 -bonded carbon atoms and possessing highly …

This review discusses the application of alpha particle-emitting radionuclides in targeted
radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth-212, …

Tumors build vessels by cooption of pre-existing vasculature and de novo recruitment of bone
marrow (BM)-derived endothelial progenitor cells (EPCs). However, the contribution and …

The potential of α-particle emitters to treat cancer has been recognized since the early 1900s.
Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry…

The molecular weight cutoff for glomerular filtration is thought to be 30–50 kDa. Here we
report rapid and efficient filtration of molecules 10–20 times that mass and a model for the …

A novel α-particle emitting monoclonal antibody construct targeting the external domain of
prostate-specific membrane antigen (PSMA) was prepared and evaluated in vitro and in vivo. …

Purpose: Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia
cells and has modest single-agent activity against acute myeloid leukemia (AML). To …